Aortic cell apoptosis in rat primary aldosteronism model

Abstract

This study aimed to determine whether aldosterone could induce vascular cell apoptosis in vivo. Thirty-two male rats were randomly divided into 4 groups: vehicle (control), aldosterone, aldosterone plus eplerenone or hydralazine. They were then implanted with an osmotic mini-pump that infused either aldosterone or the vehicle. Systolic blood pressure (SBP) was measured weekly by the tail-cuff method. After 8 weeks, plasma aldosterone concentration (PAC) and renin activity (PRA) were determined by radioimmunoassay. Aortic apoptosis was examined by TUNEL assay. The levels of cytochrome c and caspase-3 were determined by Western blotting and the expression of Bax and Bcl-2 was detected by immnuohistochemistry and Western blotting. The results showed that as compared with control group, aldosterone-infused rats exhibited: (1) an increase in SBP; (2) significantly elevated PAC with depressed PRA; (3) elevated aortic vascular cell apoptosis accompanied with higher levels of cytochrome c and activated caspase-3; and (4) significantly up-regulated Bax protein with down-regulated Bcl-2. These effects of aldosterone were significantly inhibited after co-administration with eplerenone but not with hydralazine. It was concluded that aldosterone induced vascular cell apoptosis by its direct effect on the aorta via mineralocorticoid receptors and independently of blood pressure, which may contribute to aldosterone-mediated vascular injury.

Keywords

aldosteronism / apoptosis / mineralocorticoid receptor / aorta

References

[1] MilliezP., GirerdX., PlouinP.F., et al.. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol, 2005, 45(8): 1243-1248

[2] AmanoT., MatsubaraT., IzawaH., et al.. Impact of plasma aldosterone levels for prediction of in-stent restenosis. Am J Cardiol, 2006, 97(6): 785-788

[3] PittB., RemmeW., ZannadF., et al.. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 2003, 348(14): 1309-1321

[4] FullerP.J., YoungM.J.. Mechanisms of mineralocorticoid action. Hypertension, 2005, 46(6): 1227-1235

[5] HatakeyamaH., MiyamoriI., FujitaT., et al.. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem, 1994, 269(39): 24 316-24 320

[6] FunderJ.W., PearceP.T., SmithR., et al.. Vascular type I aldosterone binding sites are physiological mineralocor-ticoid receptors. Endocrinology, 1989, 125(4): 2224-2226

[7] HatakeyamaH., InabaS., TakedaR., et al.. 11beta-hydroxysteroid dehydrogenase in human vascular cells. Kidney Int, 2000, 57(4): 1352-1357

[8] CalleraG.E., TouyzR.M., TostesR.C., et al.. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension, 2005, 45(4): 773-779

[9] HironoY., YoshimotoT., SuzukiN., et al.. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-indued hypertension: the possible role of local renin-angiotnsin system. Endocrinology, 2007, 148(4): 1688-1696

[10] IglarzM., TouyzR.M., VielE.C., et al.. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotension system. Am J Hypertens, 2004, 17(7): 597-603

[11] Lopez-CandalesA., HolmesD.R., LiaoS., et al.. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol, 1997, 150(3): 993-1007

[12] von der ThusenJ.H., van VlijmenB.J., HoebenR.C., et al.. Induction of atherosclerotic plaque rupture in apolipoprotein E^−/− mice after adenovirus-mediated transfer of p53. Circulation, 2002, 105(17): 2064-2070

[13] KorshunovV.A., BerkB.C.. Smooth muscle apoptosis and vascular remodeling. Curr Opin Hematol, 2008, 15(3): 250-254

[14] DurandE., ScoazecA., LafontA., et al.. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation, 2004, 109(21): 2503-2506

[15] PatniH., MathewJ.T., LuanL., et al.. Aldosterone promotes proximal tubular cell apoptosis: role of oxidative stress. Am J Physiol Renal Physiol, 2007, 293(4): F1065-1071

[16] MathewJ.T., PatniH., ChaudharyA.N., et al.. Aldosterone induces mesangial cell apoptosis both in vivo and in vitro. Am J Physiol Renal Physiol, 2008, 295(1): F73-81

[17] HayashiH., KobaraM., AbeM., et al.. Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res, 2008, 31(2): 363-375

[18] SharifiA.M., SchiffrinE.L.. Apoptosis in aorta of deoxycorticosterone acetate-salt hypertensive rats: effect of endothelin receptor antagonism. J Hypertens, 1997, 15(12Pt1): 1441-1448

[19] WeiY., Whaley-ConnellA.T., HabibiJ., et al.. Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension, 2009, 53(2): 158-165

[20] LumachiF., ErmaniM., BassoS.M., et al.. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg, 2005, 71(10): 864-869

[21] StruthersA., KrumH., WilliamsG.H.. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol, 2008, 31(4): 153-158

[22] WilliamsT.A., VerhovezA., MilanA., et al.. Protective effect of spironolactone on endothelial cell apoptosis. Endocrinology, 2006, 147(5): 2496-2505

[23] LiY., SongY.H., MohlerJ., et al.. ANG II induces apoptosis of human vascular smooth muscle via extrinsic pathway involving inhibition of Akt phosphorylation and increased FasL expression. Am J Physiol Heart Circ Physiol, 2006, 290(5): H2116-2123

[24] MercerJ., MahmoudiM., BennettM.. DNA damage, p53, apoptosis and vascular disease. Mutat Res, 2007, 621(1–2): 75-86

[25] KutukO., BasagaH.. Bcl-2 protein family: implications in vascular apoptosis and atherosclerosis. Apoptosis, 2006, 11(10): 1661-1675

[26] OltvaiZ.N., MillimanC.L., KorsmeyerS.J.. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 1993, 74(4): 609-619

[27] SchnackenbergC.G., WelchW.J., WilcoxC.S.. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension, 1998, 32(1): 59-64

[28] MunzelT., KurzS., RajagopalanS., et al.. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest, 1996, 98(6): 1465-1470

[29] SharifiA.M., SchiffrinE.L.. Apoptosis in vasculature of spontaneously hypertensive rats: effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist. Am J Hypertens, 1998, 11(9): 1108-1116